BACKGROUND: Recent evidence indicates that both increased oxidative stress and an altered balance between pro- and anti-angiogenic factors such as vascular-endothelial growth factor (VEGF) and the soluble VEGF receptor (sFlt-1) contribute to endothelial dysfunction in preeclampsia. We hypothesized that chronic infusion of sFlt-1 to mimic the increase observed in preeclamptic patients would reduce plasma VEGF concentrations, increase blood pressure (BP) and vascular superoxide levels, and cause endothelial dysfunction in the pregnant rat. METHODS: Recombinant sFlt-1 was infused (500 ng/h) during days 13-18 of pregnancy. BP, fetal and placental weight, oxidative stress and vessel vasorelaxation were determined on day 18 of pregnancy. RESULTS: Plasma sFlt-1 concentrations (299 +/- 33 vs. 100 +/- 16 pg/ml; P < 0.01) and BP (117 +/- 6 vs. 98 +/- 4 mm Hg; P < 0.01) were increased, while plasma-free VEGF concentrations (570 +/- 77 vs. 780 +/- 48 pg/ml; P < 0.01) were decreased when compared to vehicle infused dams. sFlt-1 rats had smaller fetuses (1.3 +/- 0.03 vs. 1.5 +/- 0.04 g, P < 0.01) and placentas (0.41 +/- 0.01 vs. 0.47 +/- 0.02 g; P < 0.05). Placental (180 +/- 66 vs. 24 +/- 2.3 RLU/min/mg; P < 0.05) and vascular (34 +/- 8 vs. 12 +/- 5 RLU/min/mg; P < 0.05) superoxide production was increased in the sFlt-1 compared to vehicle infused rats. Vasorelaxation to acetylecholine (ACh) and sodium nitroprusside (SNP) were both decreased (P < 0.05) in the sFlt-1 infusion group compared to the vehicle and this decrease was attenuated (P < 0.05) by the superoxide scavenger Tiron. CONCLUSION: These data indicate elevated maternal sFlt-1 and decreased VEGF concentrations results in increased oxidative stress that contributes to vascular dysfunction during pregnancy.
BACKGROUND: Recent evidence indicates that both increased oxidative stress and an altered balance between pro- and anti-angiogenic factors such as vascular-endothelial growth factor (VEGF) and the soluble VEGF receptor (sFlt-1) contribute to endothelial dysfunction in preeclampsia. We hypothesized that chronic infusion of sFlt-1 to mimic the increase observed in preeclamptic patients would reduce plasma VEGF concentrations, increase blood pressure (BP) and vascular superoxide levels, and cause endothelial dysfunction in the pregnant rat. METHODS: Recombinant sFlt-1 was infused (500 ng/h) during days 13-18 of pregnancy. BP, fetal and placental weight, oxidative stress and vessel vasorelaxation were determined on day 18 of pregnancy. RESULTS: Plasma sFlt-1 concentrations (299 +/- 33 vs. 100 +/- 16 pg/ml; P < 0.01) and BP (117 +/- 6 vs. 98 +/- 4 mm Hg; P < 0.01) were increased, while plasma-free VEGF concentrations (570 +/- 77 vs. 780 +/- 48 pg/ml; P < 0.01) were decreased when compared to vehicle infused dams. sFlt-1rats had smaller fetuses (1.3 +/- 0.03 vs. 1.5 +/- 0.04 g, P < 0.01) and placentas (0.41 +/- 0.01 vs. 0.47 +/- 0.02 g; P < 0.05). Placental (180 +/- 66 vs. 24 +/- 2.3 RLU/min/mg; P < 0.05) and vascular (34 +/- 8 vs. 12 +/- 5 RLU/min/mg; P < 0.05) superoxide production was increased in the sFlt-1 compared to vehicle infused rats. Vasorelaxation to acetylecholine (ACh) and sodium nitroprusside (SNP) were both decreased (P < 0.05) in the sFlt-1 infusion group compared to the vehicle and this decrease was attenuated (P < 0.05) by the superoxide scavenger Tiron. CONCLUSION: These data indicate elevated maternal sFlt-1 and decreased VEGF concentrations results in increased oxidative stress that contributes to vascular dysfunction during pregnancy.
Authors: Jeffrey S Gilbert; Michael J Ryan; Babbette B LaMarca; Mona Sedeek; Sydney R Murphy; Joey P Granger Journal: Am J Physiol Heart Circ Physiol Date: 2007-11-30 Impact factor: 4.733
Authors: Francisco R González-Pacheco; Juan J P Deudero; María C Castellanos; María Angeles Castilla; María Victoria Alvarez-Arroyo; Susana Yagüe; Carlos Caramelo Journal: Am J Physiol Heart Circ Physiol Date: 2006-09 Impact factor: 4.733
Authors: A Makris; C Thornton; J Thompson; S Thomson; R Martin; R Ogle; R Waugh; P McKenzie; P Kirwan; A Hennessy Journal: Kidney Int Date: 2007-03-21 Impact factor: 10.612
Authors: Babbette D LaMarca; Derrick L Chandler; Lee Grubbs; Jennifer Bain; Gerald R McLemore; Joey P Granger; Michael J Ryan Journal: Am J Hypertens Date: 2007-11 Impact factor: 2.689
Authors: Zhihe Li; Ying Zhang; Jing Ying Ma; Ann M Kapoun; Qiming Shao; Irene Kerr; Andrew Lam; Gilbert O'Young; Frederick Sannajust; Peter Stathis; George Schreiner; S Ananth Karumanchi; Andrew A Protter; N Stephen Pollitt Journal: Hypertension Date: 2007-08-27 Impact factor: 10.190
Authors: Fangxian Lu; Egle Bytautiene; Esther Tamayo; Phyllis Gamble; Garland D Anderson; Gary D V Hankins; Monica Longo; George R Saade Journal: Am J Obstet Gynecol Date: 2007-10 Impact factor: 8.661
Authors: Kiran B Tam Tam; Babbette Lamarca; Marietta Arany; Kathy Cockrell; Lillian Fournier; Sydney Murphy; James N Martin; Joey P Granger Journal: Am J Hypertens Date: 2010-08-19 Impact factor: 2.689
Authors: Ashley K Woods; Darren S Hoffmann; Christine J Weydert; Scott D Butler; Yi Zhou; Ram V Sharma; Robin L Davisson Journal: Hypertension Date: 2010-11-15 Impact factor: 10.190
Authors: Jeffrey S Gilbert; Christopher T Banek; Ashley J Bauer; Anne Gingery; Hans C Dreyer Journal: Am J Physiol Regul Integr Comp Physiol Date: 2012-07-18 Impact factor: 3.619